ArticleMolecular biology reports2026
Molecular signatures of hypertension in polycystic ovary syndrome: Endothelin-1 and CYP11A1 as biomarkers of vascular and metabolic dysfunction.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NPC1L1, stabilized by PABPC1/IGF2BP1, accelerates atherosclerosis by enhancing CYP11A1-mediated mitophagy and ferroptosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic Ovary Syndrome (PCOS) is a complex endocrine syndrome impacting women during their reproductive phase of life and is increasingly recognized for its association with cardiovascular comorbidities, particularly hypertension. Despite its clinical significance, the hypertensive PCOS (H-PCOS) remains poorly characterized at the molecular level. METHODS AND
resultsThe current study aimed to investigate the gene expression profiles of Endothelin-1 (ET-1) and Cytochrome P450 family 11subfamilly A member 1(CYP11A1) to elucidate their potential roles in the vascular and metabolic disturbances observed in H-PCOS. A total of 69 Kurdish women aged 18 to 53 were enrolled and classified into three groups: PCOS without hypertension, hypertensive PCOS, and healthy controls. Using qRT-PCR, we measured gene expression levels and assessed serum gonadotropin hormones and lipid profiles. ROC analysis showed that ET-1 (AUC = 0.8667, p = 0.0003) and CYP11A1 (AUC = 0.7667, p = 0.009) had significant diagnostic value, while fold-change analysis revealed approximately 13.5-fold and 82-fold increases, respectively, in H-PCOS patients compared with controls and non-hypertensive PCOS, confirming a statistically robust upregulation of both genes. Gene expression levels and clinical measurements including body mass index (BMI), Luteinizing Hormone to Follicle-Stimulating Hormone (LH/FSH) ratio, and Mean Arterial Pressure (MAP) were strongly correlated. H-PCOS was clearly separated from other groups using receiver operating characteristic (ROC) analysis for ET-1, CYP11A1, BMI, and the Total Cholesterol to High Density Lipoprotein-Cholesterol (TC/HDL-C) ratio.
conclusionThese findings highlight that endocrine and vascular irregularities are key features of genetic profile of H-PCOS. ET-1 and CYP11A1 can be used as potential biomarkers to better guide H-PCOS diagnosis of hypertension and therapy.
Indexed as
Identifiers
41528595What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.